Robert Harrington to Creatinine
This is a "connection" page, showing publications Robert Harrington has written about Creatinine.
Connection Strength
0.597
-
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016 Dec 13; 134(24):1918-1930.
Score: 0.130
-
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. Am Heart J. 2016 Aug; 178:1-8.
Score: 0.125
-
Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. Am Heart J. 2012 Nov; 164(5):689-697.e3.
Score: 0.098
-
Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting. Am J Cardiol. 2010 Dec 15; 106(12):1728-34.
Score: 0.085
-
Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008 Mar 11; 51(10):991-6.
Score: 0.071
-
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. Am Heart J. 2011 Nov; 162(5):884-892.e1.
Score: 0.023
-
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010 Sep 24; 144(1):36-41.
Score: 0.019
-
Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007 Nov 15; 100(10):1538-42.
Score: 0.017
-
Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant. 2005 Oct; 20(10):2105-12.
Score: 0.015
-
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003 Jul 29; 108(4):399-406.
Score: 0.013